Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091499 | 0.83 | IDO1 (0.39) | PPARAGRM2GRM3KDM5AKDM5B | |
| SCHEMBL2092207 | 0.83 | DAO (0.41) | MAOBMAOADAOGRM2GRM3 | |
| SCHEMBL5536259 | 0.80 | PTPN7 (0.43) | — | |
| SCHEMBL5546548 | 0.80 | KIF11 (0.45) | DAOCYP11B2 | |
| SCHEMBL98902 | 0.79 | MAOB (0.41) | MAOBRIPK1 | |
| SCHEMBL5537209 | 0.78 | EPHX2 (0.44) | — | |
| SCHEMBL5540435 | 0.78 | KCNN4 (0.40) | — | |
| SCHEMBL95538 | 0.77 | IDO1 (0.52) | MAOBMAOA | |
| SCHEMBL7889545 | 0.76 | MAOB (0.47) | MAOBMAOAACHEHTTALDH1A1 | |
| SCHEMBL11313592 | 0.76 | TTR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177168-A4 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-06-25 | — | — | EP | claimed |
| JP-2002541237-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1177168-A1 | CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2000061542-A1 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2000-10-19 | — | — | WO | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1177168-A4 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1177168-A1 | CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000061542-A1 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAOB 2140/4885MAOA 2885/4885ACHE 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.